


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims


1. (Currently Amended) A compound having the formula (I):



(I)

wherein:

R¹ is selected from:



and , unsubstituted or substituted with one or more substituents selected from: halogen, -R², -O-R², -CN, -N(R²)₂,

Y is selected from: wherein the CH₂ moiety is bound to Z and


the cyclopropyl moiety is bound to R¹, , -R³- and

-R³-O-R³-, where C' and C'' are each independently directly or indirectly bound to an R¹ phenyl ring to form a 5 to 7 member fused ring;

Z is absent or is selected from O, C₁₋₆alkyl, C₁₋₆alkylene, C₁₋₆alkenyl, C₁₋₆alkenylene, C(O), S, SO, SO₂, NR⁴, where R⁴ is hydrogen, C₀₋₆alkyl or C₀₋₆alkenyl, where said alkyl, ~~or~~ alkenyl, alkylene or alkenylene is unsubstituted or is substituted with one or more substituents selected from: halogen, -R⁵, -O-R⁵, -CN, -N(R⁵)₂;

A and B are each independently C₀₋₄alkyl, where a ring is formed comprising A and B, ~~where an individual carbon atom in A and an individual carbon atom in B optionally bridge said ring~~, where each member of said ring is independently unsubstituted or substituted with one or more substituents selected from halogen, -R⁶, -O-R⁶, -CN, -N(R⁶)₂;

W is absent or is selected from ~~from O, C₀₋₆alkyl, C₀₋₆alkylene, C₀₋₆alkenyl, C₀₋₆alkenylene, C(O), S, SO, SO₂, NR⁷~~, where said alkyl, ~~or~~ alkenyl, alkylene or alkenylene is unsubstituted or is substituted with one or more substituents selected from halogen, -R⁸, -O-R⁸, -CN, -N(R⁸)₂;




is unsubstituted or is substituted with one or more substituents selected from halogen, -R⁹, -O-R⁹, -CN, -N(R⁹)₂;

R², R³, R⁴, R⁵, R⁶, R⁷, R⁸ and R⁹ are each independently hydrogen, C₀₋₆alkyl, C₀₋₆alkenyl unsubstituted or substituted with one or more halogen;

or a and pharmaceutically acceptable salt salts thereof, or an ~~and~~ individual ~~and diastereomers~~ diastereomer thereof.

2. (Currently Amended) A compound of Claim 1, wherein:

R¹ is , unsubstituted or substituted with halogen or -R², where R² is C₁₋₆alkyl;

Y is -C₁₋₆alkyl, independently unsubstituted or substituted with one or more halogen;


Z is O;

A and B are each independently C₀₋₄alkyl;

W is absent;


~~or a and pharmaceutically acceptable salt salts thereof or an enantiomer or diastereomer and individual enantiomers and diastereomers thereof.~~

3. (Currently Amended) A compound having the formula (Ia):



(Ia)


wherein:

R^1 is , unsubstituted or substituted with halogen or $-R^2$, where R^2 is C_{1-6} alkyl, independently unsubstituted or substituted with one or more halogen;

Y is $-C_{1-6}$ alkyl, independently unsubstituted or substituted with one or more halogen;


~~or a and pharmaceutically acceptable salt salts thereof or an enantiomer or diastereomer and individual enantiomers and diastereomers thereof.~~

4. (Currently Amended) A compound having the formula (Ib):



(Ib)

wherein:


R¹ is , unsubstituted or substituted with halogen or -R², where R² is C₁-6alkyl, unsubstituted or substituted with one or more halogen;

the cyclopentyl group is unsubstituted or substituted with 1-3 fluorine;

Y is -C₁-6alkyl, unsubstituted or substituted with one or more halogen;


or a and pharmaceutically acceptable salt-salts thereof or an enantiomer or diastereomer and individual enantiomers and diastereomers thereof.

5. (Currently Amended) A compound having the formula (Ic):



(Ic)

wherein:

R¹ is , unsubstituted or substituted with halogen or -R², where R² is C₁-6alkyl, unsubstituted or substituted with one or more halogen;


R⁴ is hydrogen or C₀-6alkyl unsubstituted or substituted with one or more halogen;


the cyclopentyl group is unsubstituted or substituted with 1-3 fluorine;


Y is -C₁-6alkyl, unsubstituted or substituted with one or more halogen;


or a and pharmaceutically acceptable salt salts thereof or an enantiomer or diastereomer ~~and individual enantiomers and diastereomers~~ thereof.


6. (Currently Amended) A compound of claim 1 selected from:














or a and pharmaceutically acceptable salt salts thereof, or an enantiomer or diastereomer and individual and diastereomers thereof.

7. (Original) A pharmaceutical composition comprising an inert carrier and a therapeutically effective amount of a compound according to Claim 1.

8. (Original) The pharmaceutical composition according to Claim 7, further comprising a second therapeutic agent selected from the group consisting of: (i) non-steroidal anti-inflammatory agents; (ii) COX-2 inhibitors; (iii) bradykinin B1 receptor antagonists; (iv) sodium channel blockers and antagonists; (v) nitric oxide synthase (NOS) inhibitors; (vi) glycine site antagonists; (vii) potassium channel openers; (viii) AMPA/kainate receptor antagonists; (ix) calcium channel antagonists; (x) GABA-A receptor modulators (e.g., a GABA- A receptor agonist); (xi) matrix metalloprotease (MMP) inhibitors; (xii) thrombolytic agents; (xiii) opioids such as morphine; (xiv) neutrophil inhibitory factor (NIF); (xv) L-Dopa; (xvi) carbidopa; (xvii) levodopa/carbidopa; (xviii) dopamine agonists such as bromocriptine, pergolide, pramipexole, ropinirole; (xix) anticholinergics; (xx) amantadine; (xxi) carbidopa; (xxii) catechol O-methyltransferase ("COMT") inhibitors

such as entacapone and tolcapone; (xxiii) Monoamine oxidase B (“MAO-B”) inhibitors; (xiv) opiate agonists or antagonists; (xv) 5HT receptor agonists or antagonists; (xvi) NMDA receptor agonists or antagonists; (xvii) NK1 antagonists; (xviii) selective serotonin reuptake inhibitors (“SSRI”) and/or selective serotonin and norepinephrine reuptake inhibitors (“SSNRI”); (xxix) tricyclic antidepressant drugs, (xxx) norepinephrine modulators; (xxxi) lithium; (xxxii) valproate; and (xxxiii) neurontin (gabapentin).

9, 10. (canceled)

11. (Original) A method for treating or preventing pain, Parkinson’s disease, Alzheimer’s disease, epilepsy, depression, anxiety, ischemic brain injury including stroke in a patient in need thereof comprising administering to said patient a therapeutically effective amount, or a prophylactically effective amount, of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

12. (Original) A method for treating or preventing chronic, visceral, inflammatory and neuropathic pain syndromes in a patient in need thereof comprising administering to said patient a therapeutically effective amount, or a prophylactically effective amount, of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

13. (Original) A method for treating or preventing pain resulting from, or associated with, traumatic nerve injury, nerve compression or entrapment, postherpetic neuralgia, trigeminal neuralgia, diabetic neuropathy, cancer and chemotherapy, in a patient in need thereof comprising administering to said patient a therapeutically effective amount, or a prophylactically effective amount, of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof.


14. (Original) A method for treating or preventing chronic lower back pain in a patient in need thereof comprising administering to said patient a therapeutically effective amount, or a prophylactically effective amount, of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

15. (Original) A method for treating or preventing phantom limb pain in a patient in need thereof comprising administering to said patient a therapeutically effective amount, or a prophylactically effective amount, of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

16. (Original) A method for treating or preventing HIV- and HIV treatment-induced neuropathy, chronic pelvic pain, neuroma pain, complex regional pain syndrome, chronic arthritic pain and related neuralgias in a patient in need thereof comprising administering to said patient a therapeutically effective amount, or a prophylactically effective amount, of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

17. (Original) A method for treating or preventing epilepsy and partial and generalized tonic seizures in a patient in need thereof comprising administering to said patient a therapeutically effective amount, or a prophylactically effective amount, of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

18. (New) A compound selected from



or a pharmaceutically acceptable salt thereof, or an enantiomer or diastereomer thereof.